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Combinational therapyAbstract Combinational therapies are often required in the management of type 2 diabetes melli-
tus (T2DM). Among the important candidates, dipeptidyl peptidase-4 inhibitors (DPPIs) and met-
formin combination (DPPI-MET) have shown promising endeavors. In order to examine the
efﬁcacy and safety of such a combination therapy in T2DM patients ﬁnding inadequate control
with metformin, this systematic review and meta-analysis has been conducted. Literature search
was made in multiple electronic databases. Inclusion criteria included; RCTs examining the efﬁcacy
and safety of DPPI-MET against placebo-MET or MET-only groups of T2DM patients by observ-
ing changes in disease endpoints including HbA1c and FPG, and the length of trial be at least
12 weeks. Mean differences based meta-analyses were performed and heterogeneity assessment
was carried out. Nineteen studies were selected and included in the meta-analyses. DPPI-MET sig-
niﬁcantly improved all disease endpoints and the difference could be noticed up to 2 years in the
majority of outcome measures. In comparison with PBO-MET, the DPPI-MET combinational
therapy resulted in the percent HbA1c changes from baseline with a mean difference [95% CI] of
0.77 [0.86, 0.69] in 3-month (P< 0.00001), 0.67 [0.76, 0.59] in 6-month (P< 0.00001),
0.67 [0.88, 0.47] in 1-year (P< 0.00001) and 0.36 [0.53, 0.20] in 2-year trials
(P< 0.0003). Reduction in body weight and safety proﬁle in the treated and control groups were
not different. A combinational therapy with DPPI and metformin signiﬁcantly improves diabetes
clinical indicators and this effect has been observed for up to 2 years herein. Safety and tolerability
of DPPI-MET combination have been found well-manageable with a very similar adverse event
proﬁle in both treated and control groups.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Type 2 diabetes mellitus (T2DM) prevalence is increasing and
this disease could be the seventh leading cause of mortality by
2030. At present, 350 million people are suffering from this
devastating disease (WHO, 2013). Microvascular complica-
tions associated with diabetes lead to blindness, renal failure
and organ loss besides stroke and heart disease related mortal-
ity is 2–4 times more in diabetes patients (Green and Feinglos,
2008). It is a progressive disease which often requires multi-
medication strategy in order to achieve better glycemic control.
Lifestyle changes are the prime interventions after the diagno-
sis of diabetes but metformin is the ﬁrst line drug to control the
disease which may be followed by other drugs such as sulfonyl-
urea, thiazolidinediones and insulin when metformin is found
inadequate to control diabetes.
Amongst the add-on treatments, sulfonylureaand thiazolidin-
ediones were studied but because of the higher prevalence of
hypoglycemic events and other complications are considered as
low priority options. More recent developments in this ﬁeld
include utilization of glucagon like peptide analogues,
a-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors
(DPPIs) and sodium-glucose co-transporter-4 inhibitors (SGL-
TIs) which have potentials to be used as add-on treatments (Ah-
ren, 2008;Nauck et al., 2009a,b;Kurosaki andOgasawara, 2013).
Whereas, agonists of the glucagon-like peptide-1 (GLP-1)
receptor provide pharmacological levels of GLP-1 activity,
DPPIs increase concentrations of endogenous GLP-1 and glu-
cose-dependent insulinotropic polypeptide (GIP) by inhibiting
the breakdown of these incretins (Drucker and Nauck, 2006;
Kendall et al., 2009). Both these incretins improve glucose-
dependent insulin release. Meal induced glucagon secretion is
also believed to be suppressed by the GLP-1 (Deacon et al.,
2004). A number of DPPI drugs have shown efﬁcacy and tol-
erability potentials and in a meta-analysis of 62 studies, DPPIs
as monotherapy were found to decline percent HbA1c by
0.76% when compared to respective placebo or comparator
groups (Park et al., 2012).
There is no study so far to meta-analyze the efﬁcacy and
safety of the DPPI-metformin combinational therapy against
placebo-metformin or metformin only controls. This is impor-
tant to evaluate this potential combinational therapy as many
ﬁxed-dose combinations of metformin and DPPI drugs are pro-
posed andmany are in different stages of development. This sys-
tematic review andmeta-analysis therefore attempts to evaluate
the efﬁcacy and safety of the combinational therapy with met-
formin and DPPIs by examining the data generated from therandomized controlled trials (RCTs) that examined the effec-
tiveness of this combination against placebo-metformin con-
trols in T2DM patients ﬁnding metformin therapy inadequate.2. Methods
2.1. Literature search
Multiple electronic databases were searched for the identiﬁca-
tion, selection and retrieval of the required research papers.
These included Medline/Pubmed, EMBASE, SCOPUS, CI-
NAHL, Google Scholar, Science Citation Index Expanded,
Conference Proceedings Citation Index-Science, Cochrane
Central Register of Controlled Trials and the ClinicalTri-
als.gov. Search engines were used with various combinations
and phrases of the major MeSH terms including dipeptidyl
peptidase-4 inhibitors, sitagliptin, alogliptin, saxagliptin, vil-
dagliptin, linagliptin, dutogliptin, add-on treatment to metfor-
min, combinational therapy, randomized controlled trial,
efﬁcacy, safety, tolerability, and diabetes. Lists of references
of important articles were also screened for achieving compre-
hension in the literature search.
2.2. Inclusion and exclusion criteria
This meta-analysis and associated systematic review includes
RCTs that examined the efﬁcacy, safety and tolerability of
DPPIs in combination with metformin during the years 2000
to September 2013. The participants of these trials were
T2DM patients with inadequate control of disease with life-
style changes and metformin therapy. Primary outcome mea-
sures of interest were percent glycated hemoglobin (HbA1c),
fasting plasma glucose (FPG), postpandrial glucose (PPG) lev-
els, homeostatic model of assessment (HOMA)-IR (insulin
resistance) and -beta (beta cell), proinsulin–insulin ratio (PI),
and body weight changes. The inclusion criteria were: (a)
RCTs that examined the efﬁcacy and safety of DPPI-MET
against PBO-MET or MET-only groups of T2DM patients,
(b) the trials had examined the effects of intervention on at
least HbA1c and FPG as clinical indicators of disease condi-
tion, (c) Disease diagnosis in the participants achieved at least
1 year before the start of the trial and (d) Length of the trial be
at least 12 weeks. Exclusion criteria were: (a) RCTs which
compared DPPI with metformin as monotherapies, (b) RCTs
that studied DPPI-MET against PBO-MET plus other antidi-
abetic drug/s, (c) RCTs that utilized other contemporary drugs
Metformin-dipeptidyl peptidase-4 inhibitors combinational therapies in diabetes 605in combination with metformin as comparators against DPPI-
MET, and (d) trials which compared the efﬁcacy and safety of
two DPPIs in combination with metformin without a PBO-
MET or MET-only group.
2.3. Quality assessment of the trials
The Jadad scale was used to assess the quality of the RCTs in-
cluded in the meta-analysis (Jadad et al., 1996) which evaluates
reports of the RCTs under three major domains: randomiza-
tion, concealment, and trial success in terms of participant
dropout/withdrawal. The scale could award a maximum of 5
points to a RCT if it has (1) carried out randomization, (2)
provided details of randomization process in the report, (3)
carried out concealment, (4) provided sufﬁcient details of con-
cealment, and (5) provided fate of the participants i.e. drop-
outs/withdrawals etc. At least 3 out of 5 score was required
for a trial to be included in this review. The inclusion of all ran-
domized participants in the ﬁnal analysis was considered only
when at least 75% completeness of follow up was achieved.
2.4. Data extraction, synthesis and statistical analysis
Data regarding participant’s demographic, pathological and
clinical characteristics, trial design and criteria, interventions,
outcome measures and outcomes were collected from research
papers published during 2000 and 2013. Data extraction was
carried out from textual, tabular and graphic sources as per
need and later uniformity of units was ensured by using appro-
priate calculators.
Meta-analyses were carried out by using Review Manager
software (RevMan Version 5.2; Chocrane Collaboration) with
the random effects model. In the procedure, means with stan-
dard deviation (SD) values were either extracted directly or
calculated accordingly that were used as input data for calcu-
lating mean differences and conﬁdence intervals of both
groups of each study. The overall effect of treatment was based
on calculating a weighted average of the inverse varianceFigure 1 Flowchart of study retradjusted individual study effects. Heterogeneity was deter-
mined with Chi2 and I2 indices and visual examination of fun-
nel plots provided a rough indication of the publication bias.3. Results
The literature search led to the ﬁnal selection of nineteen stud-
ies after the observance of inclusion and exclusion criteria. A
summarized ﬂowchart of the literature search and study selec-
tion process has been given in Fig. 1. Table 1 contains the char-
acteristics of these studies. Of the included studies, trial
duration was 3 months (3 trials), 6 months (12 trials), 1 year
(3 trials) and 2 years (1 trial). The DPPIs studied were SITA
(7 trials), VILDA (4 trials), SAXA (3 trials), LINA (3 trials)
and ALO (2 trials). All of these trials used changes in percent
HbA1c as the primary outcome measure.
Overall, the population size of this meta-analysis is 12180
T2DM patients with inadequate control on the disease with
lifestyle interventions and metformin. Among the salient demo-
graphic features, the age of the participants was 54.86 ± 10.01
(mean ± SD), 52.4% of the participants were males and dura-
tion of disease since diagnosis was 5.15 ± 4.13 years
(mean ± SD; range 1.7 ± 3 to 7 ± 6.3). Important clinical
indicators of this sample of T2DM patients were: HbA1c
(8.3 ± 0.82), FPG (9.93 ± 2.4) and BMI (30.12 ± 4.9).
The quality of the included studies was generally good with
almost all studies scored 4/5 on Jadad scale. Sixteen studies
also mentioned the accordance of their study protocols with
the Helsinki Declaration of good practices.
A relatively higher level of heterogeneity was observed in
many comparisons but not all and in many cases, there was no
heterogeneity at all (I2 ranged from 0% to 85%). A sensitivity
analysis by making comparisons with either high dose groups
or low dose groups did not give signiﬁcant difference in the re-
sults achieved from the overall meta-analyses in the over efﬁcacy
parameters as well as in heterogeneity assessment. Publication
bias was also evident from the observation of the funnel plots
of almost all parameters and their categories (Fig. 2).ieval and selection procedure.
Table 1 Characteristics of the studies included in the systematic review and meta-analyses.
Study/drug/
duration
Participants Participant’s
characteristics
Clinical indicators Outcome
measures
Ou omes Limitations
Ahren et al. (2004,
2005)/VILDA/
52 week
Patients: 57 (31
VILDA vs 26 Placebo)
Age: 56.7 ± 9.6
Males: 77%
BMI: 29.55 ± 3.55
T2DM length: 5.55 ± 3.95
HbA1c (%): 7.7 ± 0.6
FPG (mmol/L):
9.85 ± 1.75
MET dosage: 1500–
3000 mg/d
Beta-cell function,
postmeal insulin
sensitivity, HbA1c,
FPG
Im oved beta-cell function
an ostmeal insulin sensitivity
an igniﬁcant reduction in
Hb 1c and FPG after
DP -MET treatment
Small population
size
Bergenstal et al.
(2012)/SITA/
52 week
Patients: 636 (SITA 177,
Placebo 90, Taspoglutide
10 mg 182 and 20 mg 187)
Age: 55.95 ± 9.6
Males: 55.66%
BMI: 32.47 ± 5.3
T2DM length: 5.8 ± 4.6
HbA1c (%): 7.97 ± 0.86
FPG (mmol/L):
9.61 ± 2.56
MET
dosage: P 1,500 mg/d
Primary: HbA1c
Secondary: % patients
achieving HbA1c 66.5%
and 67%, FPG, BW
Gr ter reductions in HbA1c,
FP and BW in taspoglutide
gro that SITA group. Both
sig cantly better than placebo
Placebo group
maintained by
24th week only.
Bosi et al. (2007)/
VILDA/24 week
NCT00099892
Patients: 544 (VILDA
50 mg 177,
100 mg 185 and Placebo 182)
Age: 54.2 ± 9.83
Males: 57% BMI: 32.6 ± 5.5
T2DM length: 6.3 ± 5.16
HbA1c (%): 8.4 ± 1.0
FPG (mmol/L):
9.9 ± 2.4
MET dosage:
2109 ± 315 mg/d
HbA1c, FPG and BW VI A signiﬁcantly reduced
Hb 1c and FPG
Charbonnel et al.
(2006)/SITA/
24 week
NCT0086515
Patients: 701 (237 SITA and
464 placebo groups).
Age: 54.55 ± 10
Males: 58% BMI: 31.2 ± 5.1
T2DM length: 6.3 ± 5.25
HbA1c (%): 8 ± 0.8
FPG (mmol/L):
9.55 ± 2.3
MET dosage:
> 1500 mg/d
Primary: HbA1c
Secondary: FPG,
glucose, insulin, and C-
peptide.
Sig ﬁcant reductions in
Hb 1C, FPG, and 2-h
po eal glucose
Small study
duration
DeFronzo et al.
(2008)/SAXA/
24 week
NCT00121667
Patients: 743 (SAXA-MET
2.5 mg = 192, 5 mg = 191,
10 mg = 181) and PBO-
MET= 179)
Age: 60 ± 9
Males: 58% BMI: 31.9 ± 4.3
T2DM length: 6.5 ± 5.2
HbA1c (%): 8 ± 0.5
FPG (mmol/L):
9.75 ± 2.6 MET
dosage: 1,500 and
6 2,550 mg/day
Primary: HbA1c
Secondary: FPG, 2-h
PPG, % pts achieving
HbA1c 6 7%, HOMA.
Sig ﬁcant reductions in
Hb 1c, FPG, PPG etc.
in PI-MET compared
to O-MET
Forst et al. (2010)/
LINA/12 week
NCT00309608
Patients: 333 (LINA 1 mg
65, 5 mg 66 and 10 mg 66,
glimipride 65 and placebo 71)
Age: 54.6 ± 10
Males: 51% BMI: 31.4 ± 4.8
T2DM length: 7 ± 6.3
HbA1c (%): 8.3 ± 0.8
FPG (mmol/L):
10.3 ± 2.3
MET dosage:
P 1500 mg/day
Primary: HbA1c
Secondary: FPG, 2-h
PPG, % pts achieving
HbA1c 6 7%, HOMA.
Sig ﬁcant reductions in
Hb 1c and FPG levels in
LI -MET groups
Small study
duration
Goldstein et al.
(2007)/SITA /
24 week; Williams-
Herman et al., 2009
(2010)/54 week &
104 week
NCT00103857
Patients: 1091 (182 SITA
50 mg-MET 2 g, 190 SITA
50 mg–MET 1 g, 179 SITA
100 mg, 182 MET 1 g, 182
MET 500 mg and 176 placebo
groups).
Age: 53.3 ± 9.93
Males: 49% BMI: 32 ± 6.63
T2DM length: 4.46 ± 4.45
HbA1c (%): 8.78 ± 0.95
FPG (mmol/L):
11.1 ± 2.7 MET
dosage: 1000 mg/d vs
2000 mg/d
HbA1c, FPG, 2-h PPG,
FSI, FSP, proinsulin/
insulin ratio, HOMA,
lipids and BW.
Su antial and additive
gly mic control that was
we olerated. Signiﬁcant
red tion in HbA1c, FPG
an -h PPG
Randomization
was carried out
initially for 24 week
trial that was
extended beyond
for 54 and 104 weeks.
Goodman et al.
(2009)/VILDA/
24 week
NCT00351884
Patients: 370 (VILD
248 and PBO 122)
Age: 54.7 ± 10.4
Males: 54% BMI: 31.5 ± 4.2
T2DM length: 4.46 ± 4.45
HbA1c (%): 8.6 ± 1.1
FPG (mmol/L):
11 ± 2.8
MET dosage:
1880 ± 380 mg/d vs
1932 ± 410 mg/d
Primary: HbA1c
Secondary: FPG
Sig ﬁcant reductions in
Hb 1c, FPG but no
diﬀ ence in BW
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Haak et al. (2012)/
LINA/24 week
NCT00798161
791 (LINA 5 mg = 142,
MET 500 mg
BID= 144, MET 1 g
BID= 147, LINA
2.5 mg +MET500 mg
BID= 143, LINA
2.5 mg +MET 1 g BID= 143,
PBO= 72)
Age: 55.3 ± 10.8
Males: 53.5% BMI:
29.1 ± 5.1
T2DM duration: 64% over
1 year wth 38% since 1–
5 years
HbA1c (%): 8.66 ± 0.97
FPG (mmol/L):
10.88 ± 2.7 MET
dosage: 1000 to 2000 mg/
day
Primary: HbA1c
Secondary: FPG
Initial LINA-MET therapy
was superior to MET alone
in improving glycemic Control.
A similar safety and tolerability
proﬁle, no weight gain and a
low risk of hypoglycemia was
observed
About half of the
population was not
treatment-naı¨ve.
Jadzinsky et al. (2009)/
SAXA/24 week
NCT00327015
Patients: 1306 (SAXA-MET
5 mg = 320, 10 mg = 323),
SAXA 10 mg = 335 and
MET= 328 Intake: Before
morning meal
Age: 52.1 ± 11.7
Males: 49% BMI: 30.2 ± 4.8
T2DM duration: 1.7 ± 3
HbA1c (%): 9.5 ± 1.2
FPG (mmol/L):
11.2 ± 3.1 MET dosage:
1 g to 2 g per day
Primary: HbA1c
Secondary: FPG, %
achieving HbA1c 6 ,
HOMA, AUC PPG
Signiﬁcant reductions in
HbA1c and FPG in
DPPI-MET compared to PBO-
MET
Slightly biased design
to study adverse
events in comparing
groups because of
mean exposure
time diﬀerences.
Nauck et al. (2009a,b)/
ALO/26 week
NCT00286442
Patients: 527 (213 ALO 12.5 mg,
210 ALO 25 mg and 104 placebo
groups).
Age: 55 ± 11
Males: 50%
BMI: 32 ± 5.3
T2DM length: 6 ± 5
HbA1c (%): 7.96 ± 0.8
FPG (mmol/L):
9.6 ± 2.6
MET dosage: < 1.5 g:
9.2 ± 16.3, 1.5–2 g:
70.4 ± 123 and > 2 g:
20.6 ± 36.3
Primary: HbA1c
Secondary: FPG
Signiﬁcant reductions in HbA1c
and FPG levels seen
Small study duration
Olansky et al. (2011) /
SITA /44 week
NCT00482729
Patients: 1250 (625 SITA and 621
MET monotherapy groups).
Age: 49.7 y
Males: 56.5%
BMI: 33.35
T2DM length: 3.35 y
HbA1c (%): 9.1 ± 1.3
FPG (mmol/L):
10.7 ± 3.2 MET dosage:
1000–2000 mg/day
Primary: HbA1c
Secondary: FPG, bl
lipid proﬁle, body w t
Signiﬁcant reductions in HbA1c,
FPG but no diﬀerence in BW
Patients were
allowed to use
additional
antihypertensives
but patients were
not appraised bout
this and not paid.
Pan et al. (2012)/
VILDA/24 week
NCT00822211
438 (VILDA 50 mg QD= 148,
50 mg BID= 146 ad
PBO= 144)
Age: 54.1 ± 9.9
Males: 46.8% BMI:
25.5 ± 3.2 T2DM length:
5.2 ± 4.65
HbA1c: 8.06 ± 0.84
FPG (mmol/L):
8.76 ± 2.05 MET
dosage: > 1500 mg/day
Primary: HbA1c
Secondary: FPG
Signiﬁcant reductions in HbA1c,
FPG
Raz et al. (2008)/SITA/
30 week NCT00337610
Patients: 190 (96 SITA and 94
placebo)
Age: 54.85 ± 9.5 Males:
49%
BMI: 30.25 ± 3.16 T2DM
length: 5.02 ± 4.6
HbA1c (%): 8.7 ± 0.84
FPG (mmol/L):
11.1 ± 2.07 MET
dosage: > 1500 mg/day
Primary: HbA1c
Secondary: FPG, PP
FSI, HOMA, lipids
Signiﬁcant reductions in HbA1c,
FPG, 2-h PPG, HOMA-b
Inclusion of
patients with
restricted severity.
Relatively small
study duration
Ross et al. (2012)/LINA/
12 week with extension
period NCT01012037
Participants: 491 (LINA 2.5 mg
BID= 223, 5 mg QD= 224 and
PBO= 44)
Age: 58.6 ± 10.3 Males:
57% BMI: 29.6 ± 5.1 T2Dm
duration: 4.9 ± 3.6
HbA1c (%): 7.97 ± 0.75
FPG (mmol/L):
9.17 ± 2.11
Primary: HbA1c
Secondary: FPG
Signiﬁcant reductions in HbA1c,
FPG
Small study duration
Scott et al. (2008)/SITA/
18 week NCT00541775
Patients: 271 (SITA 94,
rosiglitazone 87 and placebo 92)
Age: 55.1 ± 9.8 Males: 59%
BMI: 30.2 ± 4.9 T2Dm
duration: 4.9 ± 3.6
HbA1c (%): 7.7 ± 0.9
FPG (mmol/L):
8.78 ± 1.8 MET
dosage: P 1500 mg/day
HbA1c, FPG, FSI, ,
PI/I ratio, HOMA,
lipids.
Signiﬁcant reductions in HbA1c,
FPG, 2-h PPG, HOMA-b
Small study duration
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608 A.S. AlanaziThe major ﬁndings of the meta-analyses are presented in
Table 2. In comparison with PBO-MET, the DPPI-MET com-
binational therapy resulted in the percent HbA1c changes from
baseline with a mean difference [95% CI] of 0.77 [0.86,
0.69] in 3-month (P< 0.00001), 0.67 [0.76, 0.59] in 6-
month (P< 0.00001), 0.67 [0.88, 0.47] in 1-year
(P< 0.00001) and 0.36 [0.53, 0.20] in 2-year trials
(P< 0.0003). Heterogeneity as estimated by I2 was 67% and
78% in 6-month and 1-year trials respectively (Fig. 3).
Fasting plasma glucose also declined and the mean differ-
ence from baseline between DPPI-MET and PBO-MET along
with [95% CI] was 1.46 [2.0, 0.91] in 3 months (P<
0.00001), 1.09 [1.23, 0.95] in 6 months (P< 0.00001),
0.74 [1.00, 0.49] after 1 year (P< 0.00001) and 0.58
[1.01, 0.15] after 2 years (P< 0.005). Heterogeneity as esti-
mated by I2 was 85%, 46% and 14% in 3-month and 6-month
and 2-year trials respectively. However, a sensitivity analysis
(exclusion of Forst et al., 2010) left heterogeneity at 0% in
the comparison of 3-month trials.
The differences between DPPI-MET and PBO-MET with
regard to changes from baseline in reducing PPG levels were
also pronounced. The mean difference [95% CI]) was 2.46
[2.92, 2.0] after 3–6 month (P< 0.00001), 1.74 [2.28,
1.19] after 1 year (P< 0.00001) and 1.29 [1.98, 0.61]
after 2 year (P< 0.006) trials. Heterogeneity (I2) was 71% in
the 3–6 month trials.
The differences between DPPI-MET and PBO-MET with
regard to changes from baseline in proinsulin:insulin ratio
were signiﬁcant in up to 1 year trials but not in a 2 year trial.
The mean difference [95% CI]) was 0.05 [0.08, 0.01] after
3–6 month (P< 0.0008), 0.05 [0.08, 0.02] after 1 year
(P< 0.005) and 0.03 [0.08, 0.02] after 2 year (P= 0.28)
trials. Heterogeneity (I2) was 57% in the 3–6 month trials
and not apparent in other categories.
The differences between DPPI-MET and PBO-MET with
regard to changes from baseline in HOMA-beta were signiﬁ-
cant throughout up to 2-year trials. The mean difference
[95% CI]) was 12.6 [9.1, 16.09] after 3–6 month
(P< 0.00001), 24.7 [15.62, 33.73] after 1 year (P< 0.00001)
and 21.2 [6.72, 35.72] after 2 years (P< 0.003). Heterogeneity
(I2) was 53% in the 3–6 month trials, and 14% in a 2-year trial.
The mean difference [95% CI]) between DPPI-MET and
PBO-MET in changes from baseline in HOMA-IR was 0.4
[0.79, 0.0] after 3–6 month (P< 0.05), 1.47 [1.25, 4.18]
after 1 year (P< 0.00001) and 0.46 [0.37, 1.29] after 2 years
(P= 0.28). Heterogeneity (I2) was 46% in the 3–6-month tri-
als, and 96% in a 1-year trial.
The safety proﬁle of the DPPIs synthesized by averaging
the data of the included studies was very similar in both treated
and control groups (Table 3). The percentage of patients
encountering at least one serious AE was 2.7 and 2.7 and dis-
continuation due to any AE was 2.9 and 2.1 in the DPPI-MET
and PBO-MET groups respectively.
The effect of DPPI-MET on clinically important physiolog-
ical indicators was reported to be neutral by the majority of
studies. A synthesis based on averaging the effects on lipid
proﬁle mentioned by ﬁve studies as DPPI-MET vs PBO-
MET was total cholesterol (1.83 vs 4.43), triglyceride (1.7
vs 7), high-density lipoprotein cholesterol; HDL-C (3.87 vs
4.05), low-density lipoprotein cholesterol (3.8 vs 5.57), and
non-HDL-C (1.67 vs 5.77). These values are percent change
from baseline.
Figure 2 Funnel plot reﬂecting low-level publication bias in the meta-analysis of DPPI-MET vs PBO-MET for evaluating the mean
difference in changes from baseline in percent HbA1c.
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This study ﬁnds a signiﬁcant beneﬁcial effect of the combina-
tional therapy with DPPI and metformin for T2DM patients
when compared to the placebo-metformin combination or
only metformin. All major endpoints such as HbA1c, FPG,
PPG, PI and HOMA (-beta and -IR) exhibited statistically sig-
niﬁcant improvements which in the majority of cases persisted
up to 2 years. The maintenance of these endpoints at target
levels along with safety and tolerability is highly desirable in
T2DM management.
Although, the improvements in HbA1c, FPG and PPG were
more pronounced in the trials of up to 1 year duration they
were relatively less in the trials of longer duration. Reductions
in the mean difference in the changes from baseline between
treated and control groups for these endpoints from 3-month
trials to 2-year trial were 0.77 to 0.36 for percent HbA1c,
from 1.46 to 0.58 ng/ml for FPG and from 2.46 to
1.29 ng/ml for PPG. However, reduction in signiﬁcance levels
was also associated with the number of trials which was higher
in short-term trials and on the other only one trial could be in-
cluded in the analysis of 2 years long treatment effect.
In this meta-analysis, PI signiﬁcantly reduced in 3–6 months
and 1 year trials (by 0.5 in both durations) but the mean differ-
ence (0.3) between treated and control groups was not signiﬁ-
cant in the 2-year trial. Improvement in HOMA-beta and
HOMA-IR was signiﬁcantly better in DPPI-MET groups but
the mean differences of changes from baseline in trials of differ-
ent durations were not uniform (Table 1). However, in these
cases (PI and HOMA), analysis for over 6 month duration
was based on the least number of eligible trials.
Reports of long-term effectiveness of DPPIs are less avail-
able as compared to 6-month and 1-year trials. Whereas a
2 year long trial which compared SITA-MET and MET-only
found change from baseline in HbA1c of 1.7% in the former
and 1.3% in the latter groups (Williams-Herman et al.,2010), a comparable RCT (Seck et al., 2010) which compared
SITA-MET with glipizide-MET reported a least squares mean
change in HbA1c of 0.54% from baseline in the SITA-MET
group after 2 years of treatment. In this trial body weight de-
clined up to 1.6 kg in the SITA-MET group from baseline
whereas in the trial of Williams-Herman et al. (2010) after
104 weeks, body weight reduction was noted up to 1.2 kg
in SITA-MET group and 2.4 kg in MET-only group. So
far, the efﬁcacy and safety of SAXA-MET have been reported
for up to 3 years (Rosenstock et al., 2013).
Generally, DPPIs are considered as weight-neutral medica-
tion for T2DM (Inzucchi et al., 2012). In the present review,
the effect size of body weight reduction from baseline in 6-
month trials has been noticed as 0.6 (range, 0.1 to
1.6) kg and 0.8 (range, 0.2 to 1.6) kg in DPPI-MET
and PBO-MET groups respectively. One year long trials have
noticed changes in body weight from baseline as 1.1 kg in
SITA-MET and 1.2 kg in MET-only group (Olansky et al.,
2011), up to 1.7 kg in SITA-MET group and 1.5 kg in
MET-only groups (Williams-Herman et al., 2009) and
0.2 kg in both VILDA-MET and PBO-MET groups (Ahren
et al., 2005). Goodman et al. (2009) noted no reduction in body
weight of VILDA-MET treated patients against 0.69 kg reduc-
tion in PBO-MET group. Raz et al. (2008) also found no
meaningful between-group (SITA-MET vs PBO-MET) differ-
ence in body weight change in a 30-week trial. However,
DeFronzo et al. (2008)have noted an inverse relationship
between increasing doses of SAXA-MET and mean changes
from baseline in body weight (1.43, 0.87, and 0.53 kg
for 2.5, 5, and 10 mg) at week 24 of treatment.
The contemporaneous of DPPI-MET is not yet fully clear as
some other drugs have shown comparable efﬁcacy and safety
properties in RCTs. The GLP-1 receptor analogues (GLPA)
such as liraglutide and exenatide have been found to be superior
when co-administered withmetformin with amean difference of
0.53% between DPPI-MET and GLPA-MET in declining
Table 2 Major ﬁndings of the meta-analysis.
Parameter/
duration
Study groups Participants Change from baseline (mean ± SD) Mean diﬀerence [95% C ] Signiﬁcance level Heterogeneity (I2) (%)
SGLTI Placebo
HbA1c
After 3 months 6 1175 0.5 ± 0.7 0.24 ± 0.7 0.77 [0.86, 0.69] P< 0.00001 0
After 6 months 22 8364 0.85 ± 0.1 0.19 ± 0.9 0.67 [0.76, 0.59] P< 0.00001 67
After 1 year 6 2125 1.15 ± 1 0.47 ± 1 0.67 [0.88, 0.47] P< 0.00001 78
After 2 years 2 352 1.6 ± 0.9 1.2 ± 0.8 0.36 [0.53, 0.20] P< 0.0001 0
FPG
After 3 months 6 1148 1.3 ± 1.67 0.16 ± 1.66 1.46 [2.0, 0.91] P< 0.00001 85
After 6 months 22 8335 1 ± 2.2 0 ± 2.25 1.09 [1.23, 0.95] P< 0.00001 46
After 1 year 4 1735 2.4 ± 2.3 1.6 ± 2.46 0.74 [1.00, 0.49] P< 0.00001 0
After 2 years 2 351 2.9 ± 2.3 1.62 ± 2.4 0.58 [1.01, 0.15] P< 0.005 14
PPG
After 3–
6 months
14 3665 2.5 ± 3.37 0.2 ± 3.2 2.46 [2.92, 2.0] P< 0.00001 71
After 1 year 2 461 5.99 ± 3 4.24 ± 3 1.74 [2.28, 1.19] P< 0.00001 0
After 2 years 2 284 6.1 ± 2.9 4.8 ± 2.9 1.29 [1.98, 0.61] P< 0.006 0
Proinsulin/insulin ratio
After 3–
6 months
9 1990 0.2 ± 0.36 0.1 ± 0.42 0.05 [0.08, 0.01] P= 0.0007 57
After 1 year 2 419 0.2 ± 0.83 0.1 ± 0.9 0.05 [0.08, 0.02] P< 0.005 0
After 2 years 2 233 0.19 ± 0.8 0.16 ± 0.2 0.03 [0.08, 0.02] P= 0.28 0
HOMA-beta
After 3–
6 months
9 3040 12 ± 34.7 0 ± 35.4 12.6 [9.10, 16.09] P< 0.00001 53
After 1 year 2 504 38.3 ± 52 13.6 ± 51.5 24.7 [15.62, 33.73] P< 0.00001 0
After 2 years 2 316 47.4 ± 60 27 ± 60 21.2 [6.72, 35.72] P< 0.003 14
HOMA-IR
After 3–
6 months
9 1906 0.8 ± 2.86 0.5 ± 2.87 0.4 [0.79, 0.00] P< 0.05 46
After 1 year 3 561 1.37 ± 2.8 2.83 ± 3.4 1.47 [1.25, 4.18] P< 0.00001 96
After 2 years 2 316 1.3 ± 3.66 1.75 ± 3.7 0.46 [0.37, 1.29] P= 0.28 0
Weighted mean difference [95% CI].
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Figure 3 Efﬁcacy of DPPI-MET combinational therapy in declining percent HbA1c in trials of various durations; (A) 3-month, (B) 6-
month, (C) 1-year, and (D) 2-year. Please note that, keeping in view the similar effects of different doses, two doses of some studies are
included in the analyses as sensitivity analyses did not note much difference. Study identiﬁcation has been indicated as a/b and dosage
details are presented in Table 1.
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Table 3 Prevalence of adverse events in the included studies*.
Adverse events (AE) C T
At least one AE 56.0 56.3
At least one drug-related AE 11.9 12.5
At least one serious AE 2.7 2.9
Discontinuation due to AE 2.7 2.1
Back pain 3.1 2.2
Inﬂuenza 3.4 3.2
Abdominal pain 2.8 2
Arthralgia 2.4 1.5
Nausea 3.5 3.6
Vomiting 1.4 1.8
Diarrhea 5.7 5.8
Constipation 1.7 1.6
Gastrointestinal 15.7 17.7
Urinary tract infection 3.6 4
Pain in extremity 3.9 3
Headache 3.4 4.8
Nasopharyngitis 6.9 7.1
Respiratory tract infection 2.9 2.2
Hypoglycemia 2.8 2.1
Hypertension 3.6 3.4
* Only those AEs are included which are mentioned by at least ﬁve
studies.
612 A.S. AlanaziHbA1c (Pratley et al., 2010, 2011; Bergenstal et al., 2012). A sim-
ilar ﬁnding has also been reported by Aroda et al. (2012) who
compared DPPIs with GLPAs in a meta-analysis and found a
superiority of GLPAs of about 0.5% in declining HbA1c. One
RCT which compared SGLTI-MET with DPPI-MET found
the former combination better in declining percent HbA1c with
a mean difference of 0.37% between canagliﬂozin-MET and
SITA-MET (Schernthaner et al., 2013). DPPI-MET therapy
has also been suggested to be upper hand tometformin up-titra-
tion because of low gastrointestinal side effects in the former
intervention (Filozof et al., 2010; Hermans et al., 2012).
Lesser availability of longer duration RCTs for this study
was an important limitation which might be overcome to some
extent in coming years when the results of some ongoing trials
will be available. Higher levels of statistical heterogeneity
observed in many comparisons may also be considered as a lim-
itation. Sensitivity analyses could reduce heterogeneity signiﬁ-
cantly at least in one comparison in which I2 declined from
85% to 0% when a single trial was excluded (see para 6 of Sec-
tion 3). To which extent it was attributable to clinical and meth-
odological heterogeneity could not be elucidated. However, the
age of the participant population deviated 10 years from the
mean (54) and mean duration of disease since diagnosis was
5.15 with a standard deviation of 4.13 and range of 1.7–
7.0 years. Furthermore BMI deviated about 5 from a mean of
30, though relatively smaller deviations were noted for major
clinical indicators. In multi-center and multi-national trials eth-
nicity may also contribute to overall heterogeneity.
5. Conclusion
A combinational therapy with DPPI and metformin signiﬁ-
cantly improves diabetes clinical indicators. This study has ob-
served the persistence of effect for up to 2 years but the efﬁcacy
of DPPI-MET combination therapy has been reported beyondthis period. Analysis of the body weight effect of this combina-
tion revealed that DDPIs are weight neutral drugs and slight
decrease in body weight because of this therapy was attribut-
able to metformin. Safety and tolerability of this combina-
tional therapy have been found well-manageable with a very
similar adverse event proﬁle in both treated and control
groups. Therefore, this study ﬁnds that combinational therapy
with a DPPI and metformin is a valuable strategy especially as
second line therapeutic option, however, availability of more
data in a few years will clarify the position of DPPIs in the
armamentarium against diabetes and possibly more speciﬁc
prescription.References
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